Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Phase III Revlimid Data Show Survival Advantage In Multiple Myeloma Patients

This article was originally published in The Pink Sheet Daily

Executive Summary

Trial also showed longest median time to disease progression, 11.3 months, reported in previously treated MM patients in a Phase III study.

You may also be interested in...



Vidaza Key To Celgene’s $2.9 Billion Pharmion Purchase

Celgene gains first myelodysplastic syndromes therapy to show survival benefit in high-risk patients, as well as full control of multiple myeloma therapy thalidomide and late-stage candidates.

Celgene’s Revlimid Approved For Second-Line Multiple Myeloma

Firm will begin shipping 15 mg and 25 mg tablets at the end of the first week of July following sNDA approval announced June 29.

MorphoSys, After Its Commercial Debut, Looks To The Next Growth Phase

Interview: CEO Jean-Paul Kress talked to Scrip about the US launch of Monjuvi, commercial expansion and the aspiration to build a European biotech that can compete in the big leagues.

Topics

UsernamePublicRestriction

Register

PS065406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel